A. Spannheimer

[Costly type 2 diabetes mellitus. Does diabetes cost 20 billion per year?].

A. Liebl, B. Henkel, A. Goertz, 2000, MMW Fortschritte der Medizin.

[Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study].

A. Liebl, U. Reitberger, A. Spannheimer, 2002, Medizinische Klinik.

PCV33: COST-ANALYSIS OF CABG SURGERY IN PATIENTS WITH AND WITHOUT RETHORACOTOMY FROM THE HOSPITAL PERSPECTIVE IN GERMANY

W. Dietrich, T. Schlereth, I. Thate-Waschke, 2001 .

Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany--results from the CODE-2 study.

H Stammer, B. Wieseler, A. Liebl, 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[Costs of type 2 diabetes in Germany. Results of the CODE-2 study].

A. Liebl, A. Neiss, U. Reitberger, 2001, Deutsche medizinische Wochenschrift.

Kosten des Typ-2-Diabetes in Deutschland

A. Liebl, A. Neiss, U. Reitberger, 2001 .

COMPARISON OF THERAPIES WITH TORASEMIDE OR FUROSEMIDE IN PATIENTS WITH CONGESTIVE HEART FAILURE FROM A PHARMACOECONOMIC VIEWPOINT

A. Goertz, A. Spannheimer, B. Dreckmann-Behrendt, 1998, International journal of clinical practice.

PCN3: COST ANALYSIS OF SCHIZOPHRENIA TREATMENT IN GERMANY: A COMPARISON OF OLANZAPINE, RISPERIDONE, AND HALOPERIDOL USING A CLINICAL DECISION MODEL

K. Gregor, J. Clouth, A. Spannheimer, 1999 .

[Costs of type 2 diabetes in Germany. Results of the CODE-2 study].

A. Liebl, A. Neiss, U. Reitberger, 2001, Deutsche medizinische Wochenschrift.

PCV7 Economic Evaluation of Torasimide in Congestive Heart Failure in Germany

A. Goertz, A. Spannheimer, 1998 .